The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 dose escalation/expansion study of FID-007, a novel nanoparticle paclitaxel formulation, in patients with solid tumors.
 
Jacob Stephen Thomas
No Relationships to Disclose
 
Diane Habib
No Relationships to Disclose
 
Diana L. Hanna
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim
 
Christina Linda Antoine Nakhoul
No Relationships to Disclose
 
Anastasia Martynova
No Relationships to Disclose
 
Syma Iqbal
Honoraria - BeiGene
Consulting or Advisory Role - AstraZeneca; BMS; BMS; Daiichi Sankyo/Astra Zeneca; Merck
 
Jorge J. Nieva
Stock and Other Ownership Interests - Cansera; Epic Sciences; Indee P/L; Quantgene
Consulting or Advisory Role - AADi; AstraZeneca; Bioatla; Mindmed; Naveris
Research Funding - Genentech (Inst); Merck (Inst)
Patents, Royalties, Other Intellectual Property - Patent Pending - movement and unexpected healthcare encounters
 
Denice D. Tsao-Wei
No Relationships to Disclose
 
Ming Hsieh
No Relationships to Disclose
 
Ray Yin
Stock and Other Ownership Interests - Fulgent Genetics
 
Anthony B. El-Khoueiry
Honoraria - ABL bio; Agenus; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; EISAI; EMD Serono; Exelixis; Gilead Sciences; Merck; QED Therapeutics; Qurient; Roche/Genentech; Senti Biosciences; SERVIER; Tallac Therapeutics
Consulting or Advisory Role - ABL Bio; Agenus; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Gilead Sciences; Merck; Pieris Pharmaceuticals; QED Therapeutics; Qurient; Roche; Senti Biosciences; SERVIER; Tallac Therapeutics
Research Funding - Astex Pharmaceuticals; AstraZeneca; Fulgent Genetics